Clinical Trial Update: Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of Lutetium-177-PSMA-617 in oligo-metastatic hormone-sensitive prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED